SOUTH SAN FRANCISCO, Calif., May 18, 2023 /PRNewswire/ -- SiteOne Therapeutics, Inc., a clinical-stage biopharmaceutical company developing isoform-selective inhibitors of the voltage gated sodium channel (NaV) for the treatments of pain, cough, and other conditions involving hypersensitivity of the nervous system, today announced that it has received a grant (UG3DA058552) for up to $15 million from the National Institute on Drug Abuse (NIDA) for the development of STC-004, an investigational, non-opioid treatment for acute and chronic pain conditions. The grant was awarded through the National Institutes of Health (NIH) Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, a trans-agency effort to accelerate the development of scientific solutions to the national opioid public health crisis.
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2022 /PRNewswire/ -- SiteOne Therapeutics, Inc., a clinical-stage biopharmaceutical company developing non-opioid treatments to address pain, cough and other conditions involving hypersensitivity of the nervous system, today announced that it has entered into a strategic collaboration and licensing agreement with Vertex Pharmaceuticals. Under the terms of the agreement, the companies will work together to advance potent and selective inhibitors of sodium ion channel 1.7 (NaV1.7) as non-opioid therapeutics for the treatment of pain. SiteOne will be responsible for research and early preclinical development activities, with Vertex responsible for subsequent development, and commercialization. SiteOne will receive an upfront payment and is eligible for development, regulatory and commercial milestone payments, and royalties from Vertex if the program succeeds.